Courtagen Life Sciences Announces Collaboration with Raptor Pharmaceuticals

Courtagen Life Sciences has announced an agreement with Raptor Pharmaceuticals Inc. to provide genetic testing in the clinical trial for RP103 as a potential treatment for Leigh syndrome and other mitochondrial disorders.

Leigh syndrome is a severe neurological disorder caused by genetic defects in mitochondrial or nuclear DNA affecting respiratory chain function that typically results in death within the first decade of life.

“The genetic profiling of patients is expected to elucidate important information beneficial to Raptor’s clinical trial for RP103,” said Brian McKernan, CEO of Courtagen.

McKernan continued, “We are pleased to work with Raptor Pharmaceuticals and believe that Courtagen’s mtSEEK® and nucSEEK® Next Generation Sequencing tests offer the most comprehensive mitochondrial analysis for such clinical trial work.”